Company Overview and News

 
Telco industry veteran Kevin Russell takes top job at Vocus

2018-05-21 theage.com.au
Troubled telco Vocus Group has appointed industry veteran Kevin Russell as group managing director and chief executive, replacing former boss Geoff Horth who stood down in February after "disappointing" financial results.
VOC VCMMF MTCZF MTU MGRPY

 
Telco industry veteran Kevin Russell takes top job at Vocus

2018-05-21 smh.com.au
Troubled telco Vocus Group has appointed industry veteran Kevin Russell as group managing director and chief executive, replacing former boss Geoff Horth who stood down in February after "disappointing" financial results.
VOC VCMMF MTCZF MTU MGRPY

 
Former Optus boss to lead Vocus

2018-05-21 businessnews.com.au
Vocus Communications has appointed former Optus boss Kevin Russell as managing director and chief executive, three months after Geoff Horth quit the broadband provider in the wake of an earnings warning.
VOC VCMMF

5
Spark sells 50 pct stake in services infrastructure unit to Electra Group

2018-05-03 nzherald.co.nz
Spark New Zealand is selling half of its Connect 8 services infrastructure unit to electricity distributor Electra Group, in a deal which will see Connect 8 take full ownership of Electra's telecommunication's contractor Sky Communications.
VOC VCMMF NZTCY SPKKY SPK NZTCF

 
Committee recommends against easing restrictions on Chorus' business

2018-05-03 nzherald.co.nz
Removing restrictions on the services provided by Chorus would risk distorting competition in the telecommunications market, a parliamentary committee says.
VOC VCMMF

 
Spark warns of broadband price increases under proposed changes to telecommunications regulations

2018-04-24 nzherald.co.nz
Broadband prices could increase by up to $8 a month for every household and business in the country if a bill updating the telecommunications industry is passed unchanged, Spark has warned.
VOC VCMMF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ASX:VOC / VOCUS COMMUNICATIONS LIMITED on message board site Silicon Investor.

VocalTec (VOCL) VocalTec (VOCL) VocalTec (VOCL) VOSC - Vocalscape, Inc. VOSC - Vocalscape, Inc. VOSC - Vocalscape, Inc.
iVoice, Inc (IVOC.BB) iVoice, Inc (IVOC.BB) iVoice, Inc (IVOC.BB) IVOC ( old VTPI ) IVOC ( old VTPI ) IVOC ( old VTPI )
IVOC iVoice, Inc. IVOC iVoice, Inc. IVOC iVoice, Inc. Avocent Corp. (AVCT) Avocent Corp. (AVCT) Avocent Corp. (AVCT)
VOCL: VocalTec Communications VOCL: VocalTec Communications VOCL: VocalTec Communications Communications Research Inc IVOC related old VTPI Communications Research Inc IVOC related old VTPI Communications Research Inc IVOC related old VTPI
IVOC!! The Future! IVOC!! The Future! IVOC!! The Future! IVOC - Visual Telephone International IVOC - Visual Telephone International IVOC - Visual Telephone International